Jip T. van Dinter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jip T. van Dinter has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Sebastiaan van Heesch
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
54 shared publications - Damon A. Hofman
Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584, CS, Utrecht, The Netherlands; Oncode Institute, Utrecht, The Netherlands
53 shared publications - Bob Löwenberg
Department of Hematology, Erasmus MC, Rotterdam, The Netherlands, Rotterdam, Netherlands
52 shared publications - Christian Hermann Ottensmeier
University of Liverpool
52 shared publications - Cynthia Waasdorp
Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC and University of Amsterdam, Amsterdam, the Netherlands
52 shared publications - David M. Ashley
Duke University
52 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (10)
A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics
- 29 September 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (10)
Open AccessA multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S15: Tetramer gating strategy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S15: Tetramer gating strategy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S14: A375 immunopeptidomics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S14: A375 immunopeptidomics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S11: Example of a hidden NOP resulting from a complex chromosomal rearrangement in tumor sample LUN022.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S11: Example of a hidden NOP resulting from a complex chromosomal rearrangement in tumor sample LUN022.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S8: Comparison of EasyFuse short-read fusion gene caller with long-read and WGS guided NOP identification.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S8: Comparison of EasyFuse short-read fusion gene caller with long-read and WGS guided NOP identification.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S9: Results of NOP identification using simulated sequencing data.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S9: Results of NOP identification using simulated sequencing data.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S5: Long-read transcript sequencing statistics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S5: Long-read transcript sequencing statistics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S4: Overview of somatic mutation statistics for tumor samples analyzed by WGS in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S4: Overview of somatic mutation statistics for tumor samples analyzed by WGS in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S10: A) NOP expression compared to normal genes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S10: A) NOP expression compared to normal genes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S1: RNA-guided tumor genome reconstruction.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
Figure S1: RNA-guided tumor genome reconstruction.